Short answer
Indivior Pharmaceuticals, Inc. (INDV) filed its fiscal 2025 10-K annual report with the SEC on Feb 26, 2026. It reported revenue of $1.2B (+4.3% year over year) and net income of $210M.
- Top risk flagged: FDA-required 2022 label change on SUBOXONE Film due to dental injury risk triggering ongoing product liability lawsuits
FY2025 key financial metrics · XBRL
- Revenue
- $1.2B
- +4.3% YoY
- Net income
- $210M
- +10400.0% YoY
- Operating margin
- 21.1%
- +18.5 pp YoY
- Gross margin
- 80.2%
- −0.3 pp YoY
- EPS (diluted)
- $1.64
- +8100.0% YoY
- ROE
- -214.3%
- −213.7 pp YoY
- Operating cash flow
- −$27M
- −175.0% YoY
Source: XBRL data from the Indivior Pharmaceuticals, Inc. (INDV) FY2025 10-K on SEC EDGAR. USD.
Indivior Pharmaceuticals, Inc. FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business model: specialty pharmaceuticals focused on addiction treatment and opioid dependence therapies
- Emphasis on SUBLOCADE growth driving expected decline in U.S. revenue share from international markets this year
- Increasing regulatory focus on data privacy and security with rising investments and risks related to AI integration and cyber threats
- Foreign exchange risk heightened by 85% U.S. revenue concentration in 2025 and limited active currency hedging strategy
- Noteworthy: AI-related risks and vendor use of generative AI highlighted as emerging compliance and security challenges
Management Discussion & Analysis
- Revenue increased by $87M in 2025 vs $28M in 2024 from prior year performance obligations adjustments
- No profitability or operating margin figures disclosed in the text
- No forward-looking guidance or risk outlook mentioned in the provided section
Risk Factors
- FDA-required 2022 label change on SUBOXONE Film due to dental injury risk triggering ongoing product liability lawsuits
- Exposure to U.K. Financial Services and Markets Act 2000 claims over alleged misleading disclosure about SUBOXONE product-hopping scheme
- Single or dual sourcing for most raw materials and APIs risks supply interruption with average 36-month technology transfer delay to new suppliers
- 2023 entry of a competitor’s extended-release injectable buprenorphine challenges SUBLOCADE’s market share in once-monthly OUD treatment
- Leveraged balance sheet and term loan covenants constraining financial flexibility amid potential revenue declines
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.